Note 18 - Subsequent Events (Details Textual)	May 12, 2025 USD ($) $ / shares shares	Apr. 24, 2025 shares	Apr. 22, 2025 USD ($) $ / shares shares	Mar. 31, 2025 $ / shares	Dec. 31, 2024 $ / shares	Jul. 15, 2024 $ / shares	Jul. 19, 2022 USD ($) $ / shares	Aug. 10, 2021 USD ($) $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				0.0001	$ 0.0001
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)
The 2021 Note [Member]
Debt Instrument, Face Amount | $								$ 806,000
Debt Instrument, Interest Rate, Stated Percentage								5.00%
Debt Instrument, Default Interest Rate								18.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 0.2
The 2022 Note [Member]
Debt Instrument, Face Amount | $							$ 440,000
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Debt Instrument, Default Interest Rate							18.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)							$ 0.2
Subsequent Event [Member] | Series L Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares	2,858
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.5
Warrants and Rights Outstanding, Term (Month)	5 years 6 months
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	4,285,716
Class of Warrant or Right, Callable, Price Per Share (in dollars per share)	$ 0.01
Class of Warrant or Right, Twenty Day Common Stock Share Price (in dollars per share)	1.5
Subsequent Event [Member] | May 2025 Placement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.5425
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	257,143
Class of Warrant or Right, Exercisable Period (Month)	5 years
Subsequent Event [Member] | May 2025 PIPE Financing [Member]
Proceeds from Issuance or Sale of Equity | $	$ 1,500,000
Payments of Stock Issuance Costs | $	$ 200,000
Maximum Beneficial Ownership	4.99%
Maximum Beneficial Ownership, With Notice	9.99%
Failure to Register Penalty, Percentage of Subscription Amount Every Thirty Days	2.00%
Failure to Register Penalty, Interest on Unpaid Amount	18.00%
Subsequent Event [Member] | Abeyance Shares [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares		732,000
Subsequent Event [Member] | PIPE Units [Member] | May 2025 PIPE Financing [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,500
Units Issued, Series B Preferred Shares Per Unit	1
Subsequent Event [Member] | Series B Preferred Stock [Member]
Preferred Stock, Convertible, Shares Issuable (in shares) | shares	8,574,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 0.35
Preferred Stock, Convertible, Number of Common Shares Issuable Per One-thousand Dollar of Stated Value (in shares) | shares	2,858
Preferred Stock, Convertible, Maximum Allowed Amount of Common Shares (in shares) | shares	2,202,357
Percentage of Common Stock Outstanding, Threshold for Conversion	19.99%
Subsequent Event [Member] | Series B Preferred Stock [Member] | May 2025 PIPE Financing [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,500
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Subsequent Event [Member] | Series B Preferred Stock and Series B Preferred Stock Included in Units [Member] | May 2025 PIPE Financing [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,000
Stock Issued During Period, Value, New Issues | $	$ 3,000,000
Subsequent Event [Member] | The 2021 and 2022 Notes [Member]
Long-Term Line of Credit | $	$ 1,600,000
Cardionomic's Late-stage Treatment for Acute Decompensated Heart Failure [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares) | shares			1,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001
Debt Instrument, Face Amount | $			$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage			4.00%
Debt Instrument, Term (Year)			3 years
Cardionomic's Late-stage Treatment for Acute Decompensated Heart Failure [Member] | Subsequent Event [Member] | Promissory Note [Member]
Debt Instrument, Face Amount | $			$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage			4.00%
Debt Instrument, Term (Year)			3 years